Importantly, tesofensine reduces daily food intake by approximately 49% during the initial treatment period, demonstrating powerful appetite suppression that drives the observed weight loss
Compared to the placebo group, those on NG101 experienced a 40% reduction in nausea and a 67% reduction in vomiting, with a 56% reduction in the total episodes of vomiting
This evolution matters for the before-and-after narrative because it means the early struggle with portion control and food choices gradually gives way to effortless moderation
These public disclosures are useful for consumer due diligence, but do not independently establish legal compliance, pharmacy compliance, medication quality, or clinical appropriateness
Abnormal glucose levels (i.e., impaired fasting glucose [IFG] and/or impaired glucose tolerance [IGT]) or early type 2 diabetes mellitus and Established CV disease or CV risk factors at baseline
This serves the purpose of creating a stable powder and also adds a refreshing lemon taste to the final product